The Link Between BRCA Mutation & Endothelial Function

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT01907438` - Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells	N/A
Active, not recruiting	`NCT02194387` - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members	N/A
Withdrawn	`NCT02309632` - Pancreatic Cancer Screening of High-Risk Individuals in Arkansas	N/A
Active, not recruiting	`NCT01009788` - ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer	Phase 2
Completed	`NCT01251874` - Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer	Phase 1
Completed	`NCT02197000` - A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers	N/A
Recruiting	`NCT03428802` - Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	Phase 2
Completed	`NCT03377556` - Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer	Phase 2
Recruiting	`NCT04294927` - TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention	N/A
Active, not recruiting	`NCT03943173` - Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery	Early Phase 1
Active, not recruiting	`NCT02953457` - Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation	Phase 2
Completed	`NCT01975363` - Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer	N/A
Completed	`NCT01948609` - Prospective Research of Outcomes After Salpingo-oophorectomy
Active, not recruiting	`NCT03552471` - Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Phase 1
Recruiting	`NCT02225015` - Cancer Prevention in Women With a BRCA Mutation	Phase 1
Active, not recruiting	`NCT02321228` - Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers	N/A
Recruiting	`NCT04030559` - Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	Phase 2
Terminated	`NCT01905592` - A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients	Phase 3
Active, not recruiting	`NCT02286687` - Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	Phase 2
Not yet recruiting	`NCT06392841` - Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations	Phase 2

NCT number	NCT02474264
Study type	Interventional
Source	Rabin Medical Center
Contact	David Margel, MD, PhD
Phone	+972(0)39376553
Email	sdmargel@gmail.com
Status	Recruiting
Phase	N/A
Start date	February 2015
Completion date	November 2018

The Link Between BRCA Mutation and Endothelial Function

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms